Medtronic Ear, Nose & Throat

ENT innovation revolves around a new AXiS. We’re proud to share that the Stealth AXiS™ surgical system has received FDA clearance for ENT procedures, advancing what’s possible in image-guided ENT surgery. Built on decades of navigation leadership and deep partnership with ENT surgeons, this next-generation platform is designed to advance how surgeons visualize, plan, and navigate in ENT procedures. This clearance represents a defining step for the future of ENT surgery and the patients who depend on it. More to come as we prepare for launch... https://lnkd.in/dvixndJn #MedtronicENT #MedTech #MedDevice #EngineeringtheExtraordinary

Join our webinar and explore the role of intraoperative nerve monitoring and near-infrared autofluorescence in advancing thyroid and parathyroid surgery. This session will review current clinical evidence, highlight the complementary use of these technologies, and discuss practical applications in surgical cases. Participants will gain insights to support surgical decision-making and effective patient outcomes through the integration of these tools. Register here: https://bit.ly/44yo3NK

Join this online event with Dr Joseph Scharpf, MD, FACS From 6-7pm CT on February 5th, 2026. Explore the role of intraoperative nerve monitoring and near-infrared autofluorescence in advancing thyroid and parathyroid surgery. This session will review current clinical evidence, highlight the complementary use of these technologies, and discuss practical applications in surgical cases. Participants will gain insights to support surgical decision-making and effective patient outcomes through the integration of these tools.

Medtronic ENT is proud to partner with the American Rhinologic Society (ARS) to champion its mission: to serve, represent, and advance the science and ethical practice of rhinology - all while promoting excellence in patient care. This partnership strengthens Medtronic's mission to alleviate pain, restore health and extend life. By joining forces, we are reinforcing our shared commitment to innovation, education, and outcomes that matter - for physicians and the patients they serve. https://bit.ly/46DBKuM #MedtronicENT #AmericanRhinologicSociety #Rhinology

PROPEL sinus implant is Japan’s first bioabsorbable, steroid-eluting sinus implant, designed to be placed in the sinus cavity following sinus surgery. Once implanted, PROPEL sinus implant helps maintain sinus patency while gradually releasing the steroid mometasone furoate locally over approximately 30 days. Sustained local drug delivery reduces the risk of post-surgical complications.¹ Note: Product usage represented may not be approved or cleared in all markets. This product, Japan’s first drug-eluting sinus implant, was highly recognized for providing an innovative solution for postoperative management of chronic sinusitis. Amid growing demand for technologies that reduce the risk of recurrence after sinus surgery, the device’s unique two-in-one mechanism maintains sinus patency while continuously releasing steroids for about 30 days—contributing to reduced recurrence risk and improved patient well-being. Because the implant is naturally absorbed by the body within 30–45 days, no removal procedure is required. The jury commends the company’s continuous ingenuity and innovation, which are sincerely and meticulously reflected in the product’s thoughtful design. Learn more: https://bit.ly/434wMXh About the Good Design Award Established in 1957, the Good Design Award is Japan’s leading program for the comprehensive evaluation and promotion of design, succeeding the original Good Design Selection System. Recognized globally, the award attracts participation from numerous companies and organizations both in Japan and overseas. Held annually, it aims to enhance the quality of life and leverage the power of design to address social challenges and emerging themes. The symbol of the award, the “G Mark,” is widely recognized as a mark of excellence in design. Good Design Award Official Page: https://bit.ly/47w58Ub Important safety information The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at https://bit.ly/3HERZPJ. Rx only. ¹ PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2020. US-ENT-2500381 v1.0

PROPEL sinus implant is Japan’s first bioabsorbable, steroid-eluting sinus implant, designed to be placed in the sinus cavity following sinus surgery. Once implanted, PROPEL sinus implant helps maintain sinus patency while gradually releasing the steroid mometasone furoate locally over approximately 30 days. Sustained local drug delivery reduces the risk of post-surgical complications.¹ Note: Product usage represented may not be approved or cleared in all markets. This product, Japan’s first drug-eluting sinus implant, was highly recognized for providing an innovative solution for postoperative management of chronic sinusitis. Amid growing demand for technologies that reduce the risk of recurrence after sinus surgery, the device’s unique two-in-one mechanism maintains sinus patency while continuously releasing steroids for about 30 days—contributing to reduced recurrence risk and improved patient well-being. Because the implant is naturally absorbed by the body within 30–45 days, no removal procedure is required. The jury commends the company’s continuous ingenuity and innovation, which are sincerely and meticulously reflected in the product’s thoughtful design. Learn more: https://bit.ly/3JlUOWT About the Good Design Award Established in 1957, the Good Design Award is Japan’s leading program for the comprehensive evaluation and promotion of design, succeeding the original Good Design Selection System. Recognized globally, the award attracts participation from numerous companies and organizations both in Japan and overseas. Held annually, it aims to enhance the quality of life and leverage the power of design to address social challenges and emerging themes. The symbol of the award, the “G Mark,” is widely recognized as a mark of excellence in design. Good Design Award Official Page: https://www.g-mark.org/ Important safety information The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.manuals.medtronic.com. Rx only. ¹ PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2020. US-ENT-2500381 v1.0

PROPEL sinus implant is Japan’s first bioabsorbable, steroid-eluting sinus implant, designed to be placed in the sinus cavity following sinus surgery. Once implanted, PROPEL sinus implant helps maintain sinus patency while gradually releasing the steroid mometasone furoate locally over approximately 30 days. Sustained local drug delivery reduces the risk of post-surgical complications.¹ Note: Product usage represented may not be approved or cleared in all markets. This product, Japan’s first drug-eluting sinus implant, was highly recognized for providing an innovative solution for postoperative management of chronic sinusitis. Amid growing demand for technologies that reduce the risk of recurrence after sinus surgery, the device’s unique two-in-one mechanism maintains sinus patency while continuously releasing steroids for about 30 days—contributing to reduced recurrence risk and improved patient well-being. Because the implant is naturally absorbed by the body within 30–45 days, no removal procedure is required. The jury commends the company’s continuous ingenuity and innovation, which are sincerely and meticulously reflected in the product’s thoughtful design. Learn more: https://bit.ly/3JlUOWT About the Good Design Award Established in 1957, the Good Design Award is Japan’s leading program for the comprehensive evaluation and promotion of design, succeeding the original Good Design Selection System. Recognized globally, the award attracts participation from numerous companies and organizations both in Japan and overseas. Held annually, it aims to enhance the quality of life and leverage the power of design to address social challenges and emerging themes. The symbol of the award, the “G Mark,” is widely recognized as a mark of excellence in design. Good Design Award Official Page: https://www.g-mark.org/ Important safety information The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.manuals.medtronic.com. Rx only. ¹ PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2020. US-ENT-2500381 v1.0

Don't miss this opportunity, Register today! #MedtronicEmployee

PROPEL sinus implant is Japan’s first bioabsorbable, steroid-eluting sinus implant, designed to be placed in the sinus cavity following sinus surgery. Once implanted, PROPEL sinus implant helps maintain sinus patency while gradually releasing the steroid mometasone furoate locally over approximately 30 days. Sustained local drug delivery reduces the risk of post-surgical complications.¹ Note: Product usage represented may not be approved or cleared in all markets. This product, Japan’s first drug-eluting sinus implant, was highly recognized for providing an innovative solution for postoperative management of chronic sinusitis. Amid growing demand for technologies that reduce the risk of recurrence after sinus surgery, the device’s unique two-in-one mechanism maintains sinus patency while continuously releasing steroids for about 30 days—contributing to reduced recurrence risk and improved patient well-being. Because the implant is naturally absorbed by the body within 30–45 days, no removal procedure is required. The jury commends the company’s continuous ingenuity and innovation, which are sincerely and meticulously reflected in the product’s thoughtful design. Learn more: https://bit.ly/3JlUOWT About the Good Design Award Established in 1957, the Good Design Award is Japan’s leading program for the comprehensive evaluation and promotion of design, succeeding the original Good Design Selection System. Recognized globally, the award attracts participation from numerous companies and organizations both in Japan and overseas. Held annually, it aims to enhance the quality of life and leverage the power of design to address social challenges and emerging themes. The symbol of the award, the “G Mark,” is widely recognized as a mark of excellence in design. Good Design Award Official Page: https://www.g-mark.org/ Important safety information The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.manuals.medtronic.com. Rx only. ¹ PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2020. US-ENT-2500381 v1.0